TipRanks
Go Ultimate55% OFF

Incyte (INCY) Stock Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

INCY Analyst Ratings

Moderate Buy
22Ratings
11Buy11Hold0Sell
Based on 22 analysts giving stock ratings to Incyte in the past 3 months

INCY Stock 12 Month Forecast

MXN 2,525.65▲(27.02% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is MXN 2,525.65 with a high forecast of MXN 2,950.35 and a low forecast of MXN 1,954.37. The average price target represents a 27.02% change from the last price of MXN 1,988.32.
Highest Price TargetMXN 2,950.35Average Price TargetMXN 2,525.65Lowest Price TargetMXN 1,954.37

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for MX:INCY
Price TargetFollowArticle
Canaccord GenuityMXN 2,856.39buy43.66%UpsideReiterated10/30/26
H.C. WainwrightMXN 2,856.39buy43.66%UpsideReiterated10/30/26
BarclaysMXN 2,612.09→MXN 2,687.26buy35.15%UpsideReiterated10/30/26
UBSMXN 2,386.59hold20.03%UpsideReiterated10/30/26
Morgan Stanley Analyst forecast on MX:INCYChris YuNot RankedMorgan StanleyMXN 2,236.25→MXN 2,179.88hold9.63%UpsideAssigned10/30/26
Evercore ISIMXN 2,349.01→MXN 2,386.59hold20.03%UpsideReiterated10/30/26
Stifel NicolausMXN 2,950.35buy48.38%UpsideReiterated10/30/26
GuggenheimMXN 2,856.39buy43.66%UpsideReiterated10/29/26
RBC CapitalMXN 2,142.29→MXN 2,198.67hold10.58%UpsideAssigned10/29/26
OppenheimerMXN 2,255.05→MXN 2,706.05buy36.10%UpsideUpgraded10/29/26
Wells FargoMXN 2,405.38→MXN 2,386.59hold20.03%UpsideReiterated10/29/26
Cantor Fitzgerald Analyst forecast on MX:INCYUnknown AnalystNot RankedCantor Fitzgerald―hold―Reiterated10/29/26
Truist FinancialMXN 2,161.09hold8.69%UpsideReiterated10/27/26
Bank of America SecuritiesMXN 2,630.89buy32.32%UpsideReiterated10/26/26
BMO CapitalMXN 2,442.97hold22.87%UpsideReiterated10/26/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ORKAOruka Therapeutics
ACHVAchieve Life Sciences
OVIDOvid Therapeutics
ZYMEZymeworks
CELCCelcuity

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months
Stephen Willey
Stephen WilleyStifel Nicolaus
Success Rate10/11 ratings generated profit
91%
Average Return
+14.64%

Copying Stephen Willey's trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +14.64% per trade.

1 Year
Tazeen Ahmad
Tazeen AhmadBank of America Securities
Success Rate19/19 ratings generated profit
100%
Average Return
+33.03%

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +33.03% per trade.

2 Years
Tazeen Ahmad
Tazeen AhmadBank of America Securities
Success Rate19/19 ratings generated profit
100%
Average Return
+45.53%

Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +45.53% per trade.

INCY Analyst Recommendation Trends

050100150200Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
Monthly rating counts for INCY
RatingJun 26Jul 26Aug 26Sep 26Oct 26
Strong Buy00000
Buy4040213023
Hold4141292621
Sell32000
Strong Sell00000
total8483505644

In the current month, INCY has received 23 Buy Ratings, 21 Hold Ratings, and 0 Sell Ratings. INCY average Analyst price target in the past 3 months is 2,525.65.

INCY Financial Forecast

MXN -69MXN -37MXN -5MXN 27MXN 59Q1 2026Q3 2026Q4 2026
HighMXN 57.88
ConsensusMXN 36.02
LowMXN 27.64

INCY Earnings Forecast

Next quarter’s earnings estimate for INCY is MXN 36.02 with a range of MXN 27.64 to MXN 57.88. The previous quarter’s EPS was -MXN 67.65. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

MXN 23.9BMXN 25.8BMXN 27.7BMXN 29.6BMXN 31.5BQ1 2026Q3 2026Q4 2026
HighMXN 30.2B
ConsensusMXN 29B
LowMXN 26.4B

INCY Sales Forecast

Next quarter’s sales forecast for INCY is MXN 29.00B with a range of MXN 26.44B to MXN 30.19B. The previous quarter’s sales results were MXN 29.26B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

INCY Stock Forecast FAQ

What is MX:INCY’s average 12-month price target, according to analysts?
Based on analyst ratings, Incyte’s 12-month average price target is Mex$2,525.65.
What is MX:INCY’s upside potential, based on the analysts’ average price target?
Incyte has 27.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Incyte a Buy, Sell or Hold?
Incyte has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 11 hold ratings and 0 sell ratings.
What is Incyte’s share price target?
The average share price target for Incyte is Mex$2,525.65. This is based on 22 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$2,950.35, and the lowest forecast is Mex$1,954.37. The average share price target represents a 27.02% increase from the current price of Mex$1,988.32.
What do analysts say about Incyte?
Incyte’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Street analysts.
How can I buy shares of Incyte?
To buy shares of MX:INCY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.